Lymphoma

In his new role as president and CEO of The Leukemia & Lymphoma Society, pediatric hematologist oncologist E. Anders Kolb, MD, aims to expand his life’s work in advancing blood cancer research and therapies for patients of all ages.

Aldeyra Therapeutics will seek to make its investigational drug candidate ADX-2191 available to patients with primary vitreoretinal lymphoma under an FDA expanded access program, according to a press release.

In this video, Joshua Brody, MD, discussed the results of the SWOG S1826 trial of nivolumab vs. brentuximab vedotin in advanced-stage classic Hodgkin lymphoma, which were presented at ASCO Annual Meeting.

In this video, Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, discusses the future of DLBCL and non-Hodgkin lymphoma research.

In this video, Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, discusses treatment disparities that exist for patients with DLBCL.

In this video, Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, discusses the current treatment landscape for DLBCL.

In this video, Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, discusses highlights in non-Hodgkin lymphoma from ASCO 2023.

In this video, Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, discusses the latest research on DLBCL presented at ASCO 2023.

In this video, Jing-Zhou Hou, MD, PhD, medical oncologist and hematologist, clinical instructor and co-chair of the hematological malignancies program at UPMC Hillman Cancer Center, discussed alternative therapies for lymphoma.

In this video, Jing-Zhou Hou, MD, PhD, medical oncologist and hematologist, clinical instructor and co-chair of the hematological malignancies program at UPMC Hillman Cancer Center, discussed using circulating tumor DNA to guide lymphoma therapy.